Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 13Recruiting 6Terminated 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Cytarabine 55Decitabine 33Azacitidine 30Idarubicin 22venetoclax 21fludarabine 16Cyclophosphamide 16Granulocyte Colony-Stimulating Factor 15Daunorubicin 12Mitoxantrone 9Etoposide 8Cladribine 8Busulfan 8Aclarubicin 8Homoharringtonine 7Filgrastim 7Peripheral Blood Stem Cell Transplantation 6fludarabine phosphate 5aclacinomycins 4Tretinoin 4Sorafenib 4Radiotherapy 4Polymerase Chain Reaction 4Mycophenolic Acid 4Lenalidomide 4Gemtuzumab 4Cyclosporine 4Clofarabine 4Arsenic Trioxide 4sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid, Acute × quizartinib × Clear all
NCT04112589 2022-03-14

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

PETHEMA Foundation

Phase 1/2 Unknown
63 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03135054 2020-12-10

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

The University of Hong Kong

Phase 2 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡